31 Okt 2016 Jahr - FDA held a public meeting, Pre-Market Evaluation
of Abuse-Deterrent Properties of Opioid Drug
Products, to discuss scientific and technical issues
relating to formulation development and pre-
market evaluation of opioid drug products with
abuse-deterrent properties.